Categories Earnings, Health Care

Earnings: Array BioPharma delivers strong Q2 results, investors cheer

Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology.  The top line came in well above street projection of $49.02 million.

Net loss was cut down to 5 cents per share from 17 cents per share last year. Analysts were expecting a loss of 16 cents per share.

ARRY shares popped 3.2% during pre-market trading post the earnings announcement. The stock has gained 35% in the trailing 12 months.

CEO Ron Squarer said, “We continue to be pleased with demand following the US launch of BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma, which delivered $22.7 million in net product sales during the second commercial quarter.”

BRAFTOVI + MEKTOVI net product sales soared 62% in the US compared to the prior sequential quarter. The combination has also been launched in Germany, Austria, the Netherlands, and the United Kingdom

The Boulder, Colorado-based biotechnology firm has partnered with Bristol-Myers Squibb (BMY), Merck (MRK) and Pfizer (PFE) to study numerous cancer drug combinations.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Electronic Arts (EA) Q4 earnings drop and miss estimates; revenue down 3%

Video game company Electronic Arts, Inc. (NASDAQ: EA) reported lower earnings and revenues for the fourth quarter of 2021. Earnings also missed analysts' forecast. During the March quarter, net bookings

What lies in store for Tyson Foods (TSN) this year?

Shares of Tyson Foods Inc. (NYSE: TSN) were in green territory during afternoon hours on Tuesday. The stock has gained 32% over the past 12 months and 23% since the

Virgin Galactic (SPCE) fails to impress market amid looming uncertainty

Space tourism company Virgin Galactic Holdings, Inc. (NYSE: SPCE) ended the first quarter of 2021 without generating revenue and continued the losing streak even as uncertainty over its test flight

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top